Jinxatvet 02 Rachelmelvin N Jocelinvillarreal 06 28 23 Jpg 1 Scaled Jpg Here, we describe the rationale, design, and goals of the triad randomized clinical trial, the first rigorous test of a pharmacologic intervention against biological aging with lifespan and healthspan metrics as endpoints to be performed outside of the laboratory in any species. We’ve designed a comprehensive program to study all phases of cognitive development, health, and disease through surveys, interactive games that owners play with their dogs, and even an opportunity for interested participants to donate their dog’s body to science at the end of their natural lifespan.
Dog Aging Project Researchers led by the texas a&m college of veterinary medicine & biomedical sciences (vmbs) have received $7 million from the national institutes of health (nih) to expand a clinical trial studying rapamycin’s ability to extend the lives of companion dogs as part of the dog aging project (dap). The dog aging project is a long term biological study of aging in dogs, centered at the university of washington. [1] professors daniel promislow and matt kaeberlein are the co directors of the project. Biogerontologist matt kaeberlein studies aging pets to determine how to improve healthspan in dogs and their humans. daniel promislow and matt kaeberlein are investigating whether rapamycin can increase longevity in companion dogs. hannah joined drug discovery news as an assistant editor in 2022. Tune in as dr. matt kaeberlein describes the longevity agent rapamycin and its impact on mtor and the dog aging project, which is investigating companion dogs as a model organism for aging.
Details On The Dog Aging Project And Rapamycin Trial Kaeberlein Biogerontologist matt kaeberlein studies aging pets to determine how to improve healthspan in dogs and their humans. daniel promislow and matt kaeberlein are investigating whether rapamycin can increase longevity in companion dogs. hannah joined drug discovery news as an assistant editor in 2022. Tune in as dr. matt kaeberlein describes the longevity agent rapamycin and its impact on mtor and the dog aging project, which is investigating companion dogs as a model organism for aging. Dog aging project researchers will investigate rapamycin’s ability to extend lifespan and improve health span in dogs. This video is a great talk from dr. matt kaeberlein at raadfest 2025, which took place a few weeks ago in las vegas. the first part of matt’s presentation is a great overview of the dog aging project and why companion animals (dogs) are great organisms to study the biology of aging. Rapamycin, a medication that affects both the immune system and metabolism, has been shown to increase the lifespan of mice. the primary purpose of this project is to determine whether rapamycin increases the lifespan of companion dogs. Founded by dr. matt kaeberlein, a passionate advocate for aging research, this project harnesses the power of citizen science to collect vast amounts of data from dog owners across the united states.
Details On The Dog Aging Project And Rapamycin Trial Kaeberlein Dog aging project researchers will investigate rapamycin’s ability to extend lifespan and improve health span in dogs. This video is a great talk from dr. matt kaeberlein at raadfest 2025, which took place a few weeks ago in las vegas. the first part of matt’s presentation is a great overview of the dog aging project and why companion animals (dogs) are great organisms to study the biology of aging. Rapamycin, a medication that affects both the immune system and metabolism, has been shown to increase the lifespan of mice. the primary purpose of this project is to determine whether rapamycin increases the lifespan of companion dogs. Founded by dr. matt kaeberlein, a passionate advocate for aging research, this project harnesses the power of citizen science to collect vast amounts of data from dog owners across the united states.
Comments are closed.